Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations – A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno

Česká verzia

Authors: Miloš Holánek ¹; Ondřej Bílek ¹; Rudof Nenutil ^2,3; Tomáš Kazda ⁴; Iveta Selingerová ³; Mária Zvaríková ¹; Markéta Palácová ¹; Marta Krásenská ¹; Rostislav Vyzula ^1,3; Katarína Petráková ^1,3
Authors place of work: Klinika komplexní onkologické péče, LF MU a Masarykův onkologický ústav, Brno 2 Oddělení klinické patologie, Masarykův onkologický ústav, Brno 3 RECAMO, Masarykův onkologický ústav, Brno 4 Klinika radiační onkologie, LF MU a Masarykův onkologický ústav, B ¹
Published in the journal: Klin Onkol 2019; 32(Supplementum2): 31-35
Category: Original Articles
doi: https://doi.org/10.14735/amko2019S31

Summary

Background: Mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing breast cancer. Tumors arising from this mutation are expected to be more sensitive to platinum-based drugs. The role of platinum-based drugs in systemic neoadjuvant BRCA1/2 breast cancer therapy, and its efficacy in increasing the probability of pathological complete remission (pCR) are discussed repeatedly; however, there are no clear recommendations.

Patients and methods: We retrospectively evaluated the contribution of a platinum-based antineoplastic drug to the achievement of pCR in a set of patients with BRCA1/2 mutant breast cancer treated with neoadjuvant chemotherapy from 2010 to 2017. The response to neoadjuvant chemotherapy was evaluated by a pathologist using definitive surgical specimens. A pCR was defined as a condition in which complete invasive breast cancer, and (eventually) positive lymph nodes, had disappeared.

Results: Of 76 patients (median age, 39 years; 62% with triple negative breast cancer (TNBC); 70% with BRCA1 positivity), 37 were treated with platinum-based drugs. More patients treated with platinum derivatives achieved pCR (57% vs. 23%, p = 0.005). Patients treated in a neoadjuvant setting with platinum-based antineoplastic drugs had a 4.4× greater chance of achieving pCR than those not treated with platinum, assuming the same tumor phenotype (TNBC or SR+/HER2−).

Conclusion: Neoadjuvant platinum-based chemotherapy for patients with a BRCA1/2 mutation is associated with a higher probability of achieving pCR, which is important for subsequent prognosis. This treatment should be considered particularly for patients with BRCA1 mutation and a TNBC phenotype.

This work was supported by grant of the Ministry of Health of the Czech Republic – Conceptual.

Development of a Reaserch Organization (MMCI 00209805). This work was supported by grant of the Ministry of Education, Youth and Sport of the Czech Republic (NPU I – LO1413).

The authors declare they have no potential confl icts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 21. 3. 2019

Accepted: 14. 5. 2019

Keywords:

breast cancer – genes, BRCA1 – genes, BRCA2 – neoadjuvant therapy – cisplatin – carboplatin – pathologic complete response

Zdroje

1. Svod.cz. Český národní webový portál epidemiologie nádorů. [online]. Dostupné z: http: //www.svod.cz.

2. Evans D, Gareth R, Howell A. Breast cancer risk-assessment models. Breast Cancer Res 2007; 9 (5): 213. doi: 10.1186/bcr1750.

3. Foretová L, Macháčková E, Palácová M et al. Doporučení rozšíření indikačních kritérií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. Klin Onkol 2016; 29 (Suppl 1): 9–13. doi: 10.14735/amko2016S9.

4. Petráková K, Palácová M, Schneiderová M et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2016; 29 (Suppl 1): 14–21. doi: 10.14735/amko2016S14.

5. Engel C, Fischer C. Breast cancer risks and risk prediction models. Breast Care 2015; 10 (1): 7–12. doi: 10.1159/000376600.

6. Copson ER, Maishman TC, Tapper WJ et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018; 19 (2): 169–180. doi: 10.1016/S1470-2045 (17) 30891-4.

7. Tun NM, Villani G, Ong K et al. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet 2014; 85 (1): 43–48. doi: 10.1111/cge.12270.

8. Gobbini E, Ezzalfani M, Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 2018; 96: 17–24. doi: 10.1016/j.ejca.2018.03.015.

9. Alli E, Sharma VB, Hartman AR et al. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011; 11 (1): 7. doi: 10.1186/1471-2210-11-7.

10. Bhattacharyya A, Ear US, Koller BH et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275 (31): 23899–23903. doi: 10.1074/jbc.C000276200.

11. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96 (22): 1659–1668. doi: 10.1093/jnci/djh312.

12. Adam Z, Vorlíček J, Táborská E. Protinádorová chemoterapie In: Adam Z, Vorlíček J, Koptíková J (eds). Obecná onkologie a podpůrná léčba. Praha: Grada 2003: 341–342.

13. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–172. doi: 10.1016/S0140-6736 (13) 62422-8.

14. Senkus E, Kyriakides S, Ohno S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5): 8–30. doi: 10.1093/annonc/mdv298.

15. Park CK, Jung WH, Koo JS. Pathologic evaluation of breast cancer after neoadjuvant therapy. J Pathol Transl Med 2016; 50 (3): 173–180. doi: 10.4132/jptm.2016.02.02.

16. Byrski T, Gronvald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2009; 28 (3): 375–379. doi: 10.1200/JCO.2008.20.7019.

17. Byrski T, Huzarski T, Dent R et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014; 147 (2): 401–405. doi: 10.1007/s10549-014-3100-x.

18. Telli ML, Jensen KC, Vinayak S et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation–associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 2015; 33 (17): 1895–1901. doi: 10.1200/JCO.2014.57.0085.

19. von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15 (7): 747–756. doi: 10.1016/S1470-2045 (14) 70160-3.

20. Alba E, Chacon JI, Lluch A et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012; 136 (2): 487–493. doi: 10.1007/s10549-012-2100-y.

21. Arun B, Bayraktar S, Liu DD et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011; 29 (28): 3739–3746. doi: 10.1200/JCO.2011.35.2682.

22. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115 (2): 359–363. doi: 10.1007/s10549-008-0128-9.

23. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–172. doi: 10.1016/S0140-6736 (13) 62 422-8.

24. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30 (15): 1796–1804. doi: 10.1200/JCO.2011.38.8595.

25. Spring LM, Fell G, Arfe A et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. Cancer Res 2019; 79 (Suppl 4): abstr. GS2–03. doi: 10.1158/1538-7445.SABCS18-GS2-03.

26. Masuda N, Lee SJ, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376 (22): 2147–2159. doi: 10.1056/NEJMoa1612645.